Hollings Cancer Center Planning Grant
Hollings Cancer Center Planning Grant
批准号:
6892617
负责人:
Andrew S Kraft
金额:
$26.5万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-08-24 至 2007-07-31
关键词:
African Americanapoptosisbiological signal transductioncancer preventionearly diagnosisenvironment related neoplasm /cancerhuman therapy evaluationmedically underserved populationneoplasm /cancerneoplasm /cancer diagnosisneoplasm /cancer geneticsneoplasm /cancer therapypsychological aspect of cancerrural areatelemedicine
中文摘要
霍林斯癌症中心是南卡罗来纳医科大学癌症活动的焦点。MUSC是该州医疗保健专业人员的主要生产商,是通过其附属教学医院提供的第三和第四级医疗资源。每年为校园癌症相关研究提供的资金总额约为4300万美元。自目前的肝细胞癌设施于1993年开业以来,临床量几乎增加了两倍。为了满足这些需求,MUSC已承诺出资3990万美元,在旁边建造一座13.3万平方英尺的七层塔楼。破土动工将于2001年夏天进行。肝细胞癌面临独特的环境和挑战。南卡罗来纳州有大量农村、服务不足、非裔美国人比例高的人口,在几种癌症(前列腺癌、口腔癌、宫颈癌和食道癌)中的癌症死亡率很高。这些和其他需求证明了NCI指定的综合癌症中心为南卡罗来纳州和该地区服务的关键必要性。已经发展了三个主要的基础科学项目:1)癌症生物学(信号转导和细胞凋亡),2)功能遗传学,以及3)基础和临床前治疗。P20拨款申请的另一个目标领域是转化研究计划,以补充强大的临床多学科小组,并将基础科学的发现与临床领域联系起来。针对南卡罗来纳州公民的特殊需求(遗传、环境和行为问题和障碍;早期检测项目;癌症健康结果研究),在健康、预防和控制领域启动了新的活动。将利用移动医疗单位、非裔美国人接入网络和远程医疗计划向有癌症相关需求和兴趣的南卡罗来纳州人进行研究。P20奖项将使HCC更好地实现其目标,即为该阶段的所有公民开发全面的癌症治疗方案;创造一个从基本概念到临床干预的癌症研究将得到促进的环境;并减少农村、服务不足的人口中的癌症负担。
英文摘要
The Hollings Cancer Center (HCC) is the focus of cancer activities at the Medical University of South Carolina. MUSC is the major producer of healthcare professionals in the State and a tertiary and quaternary medical resource via its affiliated teaching hospital. Funding for cancer-related research on campus totals about $43 million per year. Clinical volume has nearly tripled since the present HCC facility opened in 1993. To meet these needs, MUSC has committed $39.9 million to build an adjacent seven-story 133,000 square foot tower. Groundbreaking will occur summer of 2001. Unique circumstances and challenges face HCC. South Carolina has a large rural, underserved, high percentage African-American population and high cancer mortality rates in several cancers (prostate, oral, cervical and esophageal). These and other needs demonstrate the critical necessity for an NCI-designated comprehensive cancer center to serve South Carolina as well as the region. Three major basic science programs have been developed: 1) Cancer Biology (signal transduction and apoptosis), 2) Functional Genetics, and 3) Basic and Preclinical Therapeutics. A targeted area on additional development for this P20 grant application is a Translational Research Program to complement the strong clinical multi-disciplinary groups and bridge the discoveries in basic science to the clinical area. New activities have been initiated in Wellness, Prevention and Control that focus on particular needs of South Carolina citizens (genetic, environmental and behavioral issues and barriers; early detection projects; and cancer health outcomes research). A mobile health unit, African-American access network, and telehealth programs will be utilized to research out to the South Carolinians with cancer-related needs and interest. A P20 award will better position HCC to fulfill its goals to develop comprehensive cancer treatment options for all the citizens of the stage; create an environment where cancer research will be fostered from basic concept to clinical intervention; and reduce the cancer burden in a rural, underserved population.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Regulation of RNA Decapping and Degradation: A novel approach to prostate cancer therapy
-
批准号:10758110
-
项目类别:
-
资助金额:$39.72万
-
财政年份:2023
-
负责人:Andrew S Kraft
-
依托单位:
Pim 1 Protein Kinase in Regulating Stromal Cell Biology in Prostate Cancer
-
批准号:8855025
-
项目类别:
-
资助金额:$19.96万
-
财政年份:2015
-
负责人:Andrew S Kraft
-
依托单位:
MUSC/HCC Paul Calabresi Clinical Oncology Training Program Plan
-
批准号:8486908
-
项目类别:
-
资助金额:$16.38万
-
财政年份:2013
-
负责人:Andrew S Kraft
-
依托单位:
Targeting the Pim 1 Protein Kinase to Overcome Resistance to AKT Inhibitors
-
批准号:8577635
-
项目类别:
-
资助金额:$31.02万
-
财政年份:2013
-
负责人:Andrew S Kraft
-
依托单位:
Targeting the Pim 1 Protein Kinase to Overcome Resistance to AKT Inhibitors
-
批准号:9039263
-
项目类别:
-
资助金额:$22.86万
-
财政年份:2013
-
负责人:Andrew S Kraft
-
依托单位:
Targeting the Pim 1 Protein Kinase to Overcome Resistance to AKT Inhibitors
-
批准号:8735893
-
项目类别:
-
资助金额:$7.23万
-
财政年份:2013
-
负责人:Andrew S Kraft
-
依托单位:
Targeting the Pim 1 Protein Kinase to Overcome Resistance to AKT Inhibitors
-
批准号:9320825
-
项目类别:
-
资助金额:$31.85万
-
财政年份:2013
-
负责人:Andrew S Kraft
-
依托单位:
Targeting the Pim 1 Protein Kinase to Overcome Resistance to AKT Inhibitors
-
批准号:8891388
-
项目类别:
-
资助金额:$31.11万
-
财政年份:2013
-
负责人:Andrew S Kraft
-
依托单位:
Senior Leadership
-
批准号:8533978
-
项目类别:
-
资助金额:$6.58万
-
财政年份:2012
-
负责人:Andrew S Kraft
-
依托单位:
LIPIDOMICS SHARED RESOURCE GROUP
-
批准号:8695810
-
项目类别:
-
资助金额:$8.14万
-
财政年份:2009
-
负责人:Andrew S Kraft
-
依托单位:
CELL AND MOLECULAR IMAGING
-
批准号:8695817
-
项目类别:
-
资助金额:$7.26万
-
财政年份:2009
-
负责人:Andrew S Kraft
-
依托单位:
BIOSTATISTICS SHARED RESOURCE GROUP
-
批准号:8695824
-
项目类别:
-
资助金额:$12.18万
-
财政年份:2009
-
负责人:Andrew S Kraft
-
依托单位:
Medical University of South Carolina - Cancer Center Support Grant
-
批准号:8923675
-
项目类别:
-
资助金额:$14.74万
-
财政年份:2009
-
负责人:Andrew S Kraft
-
依托单位:
Novel Inhibitors of Pim Protein Kinases
-
批准号:7743696
-
项目类别:
-
资助金额:$25.79万
-
财政年份:2009
-
负责人:Andrew S Kraft
-
依托单位:
Medical University of South Carolina - Cancer Center Support Grant
-
批准号:8322869
-
项目类别:
-
资助金额:$5.76万
-
财政年份:2009
-
负责人:Andrew S Kraft
-
依托单位:
Medical University of South Carolina - Cancer Center Support Grant
-
批准号:7795202
-
项目类别:
-
资助金额:$155.75万
-
财政年份:2009
-
负责人:Andrew S Kraft
-
依托单位:
BIOREPOSITORY & TISSUE ANALYSIS
-
批准号:8695842
-
项目类别:
-
资助金额:$6.65万
-
财政年份:2009
-
负责人:Andrew S Kraft
-
依托单位:
Medical University of South Carolina - Cancer Center Support Grant
-
批准号:7931536
-
项目类别:
-
资助金额:$254.87万
-
财政年份:2009
-
负责人:Andrew S Kraft
-
依托单位:
CANCER CONTROL
-
批准号:8695807
-
项目类别:
-
资助金额:$3.08万
-
财政年份:2009
-
负责人:Andrew S Kraft
-
依托单位:
CELL EVALUATION & THERAPY
-
批准号:8695829
-
项目类别:
-
资助金额:$6.47万
-
财政年份:2009
-
负责人:Andrew S Kraft
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
去乙酰化酶SIRT1在前体mRNA可变剪切中的作用及其生理病理效应研究
-
批准号:31970691
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2019
-
负责人:张胜萍
-
依托单位:
TM9SF4调控非小细胞肺癌细胞凋亡机制研究
-
批准号:31900527
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2019
-
负责人:孙磊
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
姜黄素与TRAIL的协同抗肿瘤机制研究
-
批准号:31101223
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2011
-
负责人:曹林
-
依托单位:
转凝蛋白通过线粒体凋亡途径致足细胞凋亡的机制研究
-
批准号:81100502
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2011
-
负责人:管娜
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位: